PPT Slide

Clinical Development

• IND accepted by FDA

• SDT study at Mayo Clinic

• Patients with known vascular disease

• Safety, tolerability, pharmacokinetics, lipid effects

ETC-642 (RLT Peptide)

Previous slide

Next slide

Back to first slide

View graphic version